Sunday, September 27, 2020

Market Analysts see Myriad Genetics Inc. [MYGN] falling to $28. Time to buy?

Must read

Chico’s FAS Inc. [CHS] is -73.96% lower this YTD. Is it still time to buy?

Chico's FAS Inc. stock went on a downward path that fall over -1.78% on Thursday, amounting to a one-week price decrease of less...

Williams-Sonoma Inc. [WSM] gain 20.37% so far this year. What now?

Williams-Sonoma Inc. traded at a high on 09/23/20, posting a 0.59 gain after which it closed the day’ session at $88.40. The results...

Destination XL Group Inc. [DXLG] Revenue clocked in at $371.50 million, down -80.35% YTD: What’s Next?

Destination XL Group Inc. gained 4.31% or 0.01 points to close at $0.25 with a heavy trading volume of 1445013 shares. It opened...

Market Analysts see Radian Group Inc. [RDN] gaining to $21. Time to buy?

Radian Group Inc. stock went on an upward path that rose over 2.03% on Tuesday, amounting to a one-week price decrease of less...

Myriad Genetics Inc. [NASDAQ: MYGN] stock went on an upward path that rose over 2.47% on Tuesday, amounting to a one-week price decrease of less than -4.53%.

Over the last 12 months, MYGN stock dropped by -41.95%. The one-year Myriad Genetics Inc. stock forecast points to a potential upside of 13.62. The average equity rating for MYGN stock is currently 3.10, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $1.02 billion, with 74.60 million shares outstanding and 73.13 million shares in the current float. Compared to the average trading volume of 1.14M shares, MYGN stock reached a trading volume of 1290282 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Myriad Genetics Inc. [MYGN]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MYGN shares is $15.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MYGN stock is a recommendation set at 3.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

BofA/Merrill have made an estimate for Myriad Genetics Inc. shares, keeping their opinion on the stock as Underperform, with their previous recommendation back on September 26, 2019. While these analysts kept the previous recommendation, Piper Jaffray dropped their target price from $45 to $40. The new note on the price target was released on August 14, 2019, representing the official price target for Myriad Genetics Inc. stock. On August 01, 2019, analysts increased their price target for MYGN shares from 18 to 40.

The Average True Range (ATR) for Myriad Genetics Inc. is set at 0.73, with the Price to Sales ratio for MYGN stock in the period of the last 12 months amounting to 1.60. The Price to Book ratio for the last quarter was 1.11, with the Price to Cash per share for the same quarter was set at 2.91. Price to Free Cash Flow for MYGN in the course of the last twelve months was 20.28 with Quick ratio for the last quarter at 2.10.

MYGN Stock Performance Analysis:

Myriad Genetics Inc. [MYGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.53. With this latest performance, MYGN shares gained by 10.04% in over the last four-week period, additionally sinking by -22.51% over the last 6 months – not to mention a drop of -41.95% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MYGN stock in for the last two-week period is set at 54.84, with the RSI for the last a single of trading hit 51.44, and the three-weeks RSI is set at 53.99 for Myriad Genetics Inc. [MYGN]. The present Moving Average for the last 50 days of trading for this stock 12.43, while it was recorded at 13.81 for the last single week of trading, and 17.79 for the last 200 days.

Insight into Myriad Genetics Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Myriad Genetics Inc. [MYGN] shares currently have an operating margin of -21.11 and a Gross Margin at +61.31. Myriad Genetics Inc.’s Net Margin is presently recorded at -31.24.

Return on Equity for this stock declined to -19.88, with Return on Assets sitting at -12.43.

Myriad Genetics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.10 and a Current Ratio set at 2.30.

MYGN Stock EPS

With the latest financial reports released by the company, Myriad Genetics Inc. posted 0.08/share EPS, while the average EPS was predicted by analysts to be reported at 0.32/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -75.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MYGN. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Myriad Genetics Inc. go to 8.10%.

Myriad Genetics Inc. [MYGN] Insider Position Details

There are presently around $1,008 million, in the hands of institutional investors. The top three institutional holders of MYGN stocks are: BLACKROCK INC. with ownership of 12,632,423, which is approximately 1.395% of the company’s market cap and around 1.60% of the total institutional ownership; VANGUARD GROUP INC, holding 8,246,412 shares of the stock with an approximate value of $112.98 million in MYGN stocks shares; and STATE STREET CORP, currently with $73.71 million in MYGN stock with ownership of nearly 31.362% of the company’s market capitalization.

Positions in Myriad Genetics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 110 institutional holders increased their position in Myriad Genetics Inc. [NASDAQ:MYGN] by around 11,984,791 shares. Additionally, 82 investors decreased positions by around 13,037,125 shares, while 32 investors held positions by with 48,556,469 shares. The mentioned changes placed institutional holdings at 73,578,385 shares, according to the latest SEC report filing. MYGN stock had 30 new institutional investments in for a total of 2,368,618 shares, while 21 institutional investors sold positions of 9,513,221 shares during the same period.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

2U Inc. [TWOU] Revenue clocked in at $675.10 million, up 38.64% YTD: What’s Next?

2U Inc. plunged by -$0.63 during the normal trading session on Thursday and reaching a high of $33.8363 during the day while it...

W&T Offshore Inc. [WTI] Is Currently 3.49 above its 200 Period Moving Avg: What Dose This Mean?

W&T Offshore Inc. traded at a high on 09/24/20, posting a 3.49 gain after which it closed the day’ session at $1.78. The...

Tricida Inc. [TCDA] moved down -3.00: Why It’s Important

Tricida Inc. price plunged by -3.00 percent to reach at -$0.28. A sum of 1179796 shares traded at recent session while its average...

TG Therapeutics Inc. [TGTX] Stock trading around $23.74 per share: What’s Next?

TG Therapeutics Inc. loss -3.96% or -0.98 points to close at $23.74 with a heavy trading volume of 2201762 shares. It opened the...

Translate Bio Inc. [TBIO] gain 55.28% so far this year. What now?

Translate Bio Inc. closed the trading session at $12.64 on 09/24/20. The day’s price range saw the stock hit a low of $11.91,...